Sector News

Could a restructuring help protect AbbVie when revenue troubles hit?

April 15, 2015
Life sciences
It’s no secret that AbbVie’s sales are in for a shock once generic competition starts eating away at behemoth Humira. But worry not, investors: The company will be able to shield its EPS from the hit when the time comes, one analyst believes.
 
According to ISI Evercore’s Mark Schoenebaum, the Illinois pharma “has the ability to protect EPS to a far larger ability than the Street currently understands,” he wrote in a Tuesday note to investors.
 
Does that mean another Big Pharma slim-down is imminent? Not necessarily, Schoenebaum said. “I am NOT making the call that the company should (or would) immediately restructure,” he wrote. But he does hope AbbVie “will acknowledge that it, in theory, has such cost flexibility should the revenue situation underperform their expectations over the next decade.”
 
If AbbVie did decide to shed some pieces, it would hardly be alone in its thinking. More than a few of its Big Pharma peers–including Pfizer, Novartis and Merck–have recently hived off non-core assets to focus on what they do well and boost financial performance. AbbVie itself is the product of a divestment: One-time parent Abbott Labs spun the drugmaker off in early 2013.
 
Lately, though, AbbVie has been all about bulking up to ease the revenue blow when it comes. After nixing last year’s Shire tie-up on tax reasons, it recently agreed to fork over $21 billion to gain access to Pharmacyclics’ Imbruvica, a drug it said would bring it $7 billion in peak sales.
 
Still, though, $11 billion seller Humira–which brings in the vast majority of AbbVie’s top-line haul–will leave big shoes to fill. The med already has biosimilar competition in India, and with its U.S. patent protection set to expire in 2016, some industry-watchers think its business could start suffering sooner rather than later.
 
“At year 3, biosimilars will achieve 36% U.S. market share in Humira patients and 25% in established Humira patients,” Citi’s Andrew Baum wrote in February, predicting Humira revenues would decline from a peak $16 billion in 2017 to just $6 billion in 2022.
 
By Carly Helfand
 

Related News

September 25, 2020

Novo Nordisk tees up phase 3 trial for once-weekly insulin

Life sciences

People with Type 2 diabetes are no strangers to needles, with some injecting bolus insulin after meals, others injecting basal insulin once or twice a day, and others still doing […]

September 23, 2020

Novartis, Siemens to develop blood tests for multiple sclerosis

Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the companies […]

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]